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Introduction: Blisibimod is a potent B cell-activating factor (BAFF) antagonist that binds to both cell membrane-
expressed and soluble BAFF. The goal of these first-in-human studies was to characterize the safety, tolerability, and
pharmacokinetic and pharmacodynamic profiles of blisibimod in subjects with systemic lupus erythematosus (SLE).
Methods: SLE subjects with mild disease that was stable/inactive at baseline received either a single dose of blisibimod
(0.1, 0.3, 1, or 3 mg/kg subcutaneous [SC] or 1, 3, or 6 mg/kg intravenous [IV]) or placebo (phase 1a; N = 54), or four
weekly doses of blisibimod (0.3, 1, or 3 mg/kg SC or 6 mg/kg IV) or placebo (phase 1b; N = 63). Safety and tolerability
measures were collected, and B cell subset measurements and pharmacokinetic analyses were performed.
Results: All subjects (93 % female; mean age 43.7 years) carried the diagnosis of SLE for ≥ 1 year. Single- and
multiple-dose treatment with blisibimod produced a decrease in the number of naïve B cells (24–76 %) and a
transient relative increase in the memory B cell compartment, with the greatest effect on IgD-CD27+; there were
no notable changes in T cells or natural killer cells. With time, memory B cells reverted to baseline, leading to a
calculated 30 % reduction in total B cells by approximately 160 days after the first dose. In both the single- and
multiple-dosing SC cohorts, the pharmacokinetic profile indicated slow absorption, dose-proportional exposure
from 0.3 through 3.0 mg/kg SC and 1 through 6 mg/kg IV, linear pharmacokinetics across the dose range of
1.0–6.0 mg/kg, and accumulation ratios ranging from 2.21 to 2.76. The relative increase in memory B cells
was not associated with safety signals, and the incidence of adverse events, anti-blisibimod antibodies, and clinical
laboratory abnormalities were comparable between blisibimod- and placebo-treated subjects.
Conclusions: Blisibimod changed the constituency of the B cell pool and single and multiple doses of blisibimod
exhibited approximate dose-proportional pharmacokinetics across the dose range 1.0–6.0 mg/kg. The safety and
tolerability profile of blisibimod in SLE was comparable with that of placebo. These findings support further studies of
blisibimod in SLE and other B cell-mediated diseases.
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Systemic lupus erythematosus (SLE) has a heterogeneous
clinical and immunologic presentation, with the com-
monality of B cell hyperactivity across the patient popu-
lation. B cell-activating factor (BAFF, also known as B
lymphocyte stimulator [BLyS]) is crucial to the survival
and differentiation of B cells [1–5]. In animal models
of SLE, BAFF overexpression promotes features of
SLE [6–10] and BAFF antagonists attenuate disease
progression [8, 11–13]. In humans with SLE, circulat-
ing BAFF levels are increased in as many as 50 % of
patients [14–16] and numerous studies have found a
positive correlation between BAFF expression and
disease activity [17–21].
Given its likely contributory role to the maintenance
of SLE disease activity, BAFF is an appealing target in
the treatment of SLE. Two phase 3 clinical trials of the
antisoluble BAFF monoclonal antibody belimumab
added to standard-of-care treatment demonstrated
significant effects on disease activity [22, 23]. The
“peptibody” blisibimod (A-623, AMG 623) is also a
BAFF antagonist, but unlike belimumab, it binds to both
membrane-bound and soluble BAFF. Blisibimod inhibits
the interaction of BAFF with any of its three receptors
(half-maximal inhibitory concentration [IC50] = 0.2 nM at
1 nM BAFF), inhibits the in vitro BAFF-driven increases in
B cell proliferation (IC50 = 0.1 nM at 0.2 nM BAFF),
reduces in vivo peripheral B cell numbers in non-
autoimmune-prone mice, and delays the onset of
proteinuria in SLE-prone (NZBxNZW)F1 mice [24].
Neutralization of both soluble and membrane-expressed
BAFF by blisibimod may produce an immunologic change
different from that upon neutralization of soluble
BAFF alone.
We present the safety, tolerability, and pharmacoki-
netic and pharmacodynamic profiles of blisibimod in
subjects with SLE in two multicenter, double-blind,
placebo-controlled trials: a single-dose phase 1a first-in-
human study and a multiple-dose phase 1b study.
Methods
General
The studies were conducted at 12 sites in the United
States. The protocols were approved by each center’s
institutional review board (IRB) (please see the
Acknowledgements), and all subjects provided written
informed consent. The studies were developed and
sponsored by Amgen, Inc., and blisibimod is now licensed
to Anthera Pharmaceuticals, Inc. (Hayward, CA, USA).
Subjects
Men and women 18–65 years of age with mild disease
that was either stable or inactive (as assessed by the
investigator) were eligible for enrollment if they had adiagnosis of SLE for at least 1 year, and met the updated
American College of Rheumatology classification criteria
[25, 26]. Subjects were excluded if they did not have a
current or previous positive antinuclear antibody test;
had active vasculitis, central nervous system lupus, acute
renal disease, a glomerular filtration rate < 60 mL/min,
uncontrolled hypertension or diabetes, or active infec-
tion within the previous 30 days; or had antibodies to
human immunodeficiency virus, hepatitis B surface anti-
gen, or hepatitis C. Those who were pregnant or nursing
were also excluded, as were those who had either re-
ceived monoclonal antibody therapy as an investigational
drug within the previous year or participated in other
investigational drug or device trials within 30 days.
Subjects who had received cyclosporine, tacrolimus, siroli-
mus, cyclophosphamide, other alkylating agents, or the
equivalent of > 100 mg/day of prednisone (pulse therapy)
within 60 days or rituximab within 12 months were also
not eligible. However, subjects were allowed to be treated
with other SLE medications, including ≤ 10 mg/day of
prednisone or its equivalent. Other than the proscribed
medications above, investigators were permitted to pre-
scribe concomitant medications or treatments as clinically
warranted. Subjects had to be willing to practice effective
methods of contraception.
Study design
In the first-in-human phase 1a ascending single-dose
study, subjects were sequentially enrolled into one of
seven dose cohorts: 0.1, 0.3, 1.0, or 3.0 mg/kg subcuta-
neous (SC) or 1.0, 3.0, or 6.0 mg/kg intravenous (IV) bli-
sibimod. The 0.1 mg/kg dose was chosen as the starting
dose on the basis of multiple-dosing preclinical toxicol-
ogy findings in cynomolgus monkeys; the remaining
doses were based on preclinical pharmacokinetic model-
ing and toxicology studies that showed no adverse ef-
fects (AEs) at weekly doses up to 150 mg/kg IV or SC
[data on file]. Within each dose cohort, subjects were
randomized (3:1 ratio) to receive blisibimod or placebo,
and were followed for 28 (0.1 and 0.3 mg/kg) or 42 days
(1.0, 3.0, and 6.0 mg/kg) post-dose, and those in the
highest dose cohort (6.0 mg/kg) completed a 4-week ex-
tension follow-up visit after their end-of-study visit. In
the phase 1b ascending multiple-dose study, subjects
were sequentially enrolled into one of four dose cohorts:
0.3, 1.0, or 3.0 mg/kg SC or 6.0 mg/kg IV. Within each
dose cohort, subjects were randomized (4:1 ratio) to re-
ceive four weekly doses of blisibimod or placebo, and
the pharmacokinetics of blisibimod were followed to day
63 (0.3 and 1.0 mg/kg) or day 112 (3.0 and 6.0 mg/kg).
For both studies, blisibimod was given as a 30 mg/mL
formulation in vehicle. Those assigned to the placebo
group received an equivalent volume of the correspond-
ing vehicle.
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The primary end point of both studies was the
characterization of the safety and tolerability of blisibi-
mod. Safety and tolerability assessments included the
incidence of treatment-emergent AEs, and clinically
significant changes in vital signs, electrocardiograms
(ECGs), and clinical laboratory safety tests. AEs were
classified using Medical Dictionary for Regulatory
Activities (MedDRA) terminology, and clinical labora-
tory results were assessed using the grading criteria of
the National Institute of Health Common Toxicity
Criteria for Adverse Events (NIH CTCAE). Secondary
end points were the pharmacokinetic and pharmacody-
namic profiles of blisibimod following single or multiple
SC or IV doses. Exploratory end points included changes
in peripheral blood B cell counts and expression of B cell
surface markers.
Pharmacokinetic analysis
Serum concentrations of blisibimod were assessed at
each visit beginning on day 1 (the day before dosing)
and continuing through the end of the studies, with ex-
tensive serum collections after the first and fourth doses
(phase 1b study only). Pharmacokinetic parameters were
derived for each subject from the blisibimod serum con-
centrations: these parameters included area under the
plasma-concentration curve from time of treatment to the
last measurable concentration (AUC0-t), maximum ob-
served serum concentration (Cmax), estimated initial con-
centration after IV bolus dosing (C0), time to Cmax (tmax),
half-life (t1/2,z), clearance (CL), apparent clearance after SC
dosing (CL/F), and accumulation ratio (AR). Blisibimod
concentrations over time, as well as pharmacokinetic par-
ameter values were summarized by route and dose.
Immunogenicity analysis
The presence of neutralizing serologic reactivity to blisi-
bimod was analyzed using two validated assays at
screening in both studies, at the end of the phase 1a
study, and on day 29 in the phase 1b study. The first
was a Biacore immunoassay to establish the presence of
binding antibodies, and the second was an in vitro cell-
based bioassay to detect neutralizing or inhibitory effects
toward blisibimod in pre- and post-dose samples. All
samples that tested positive in the immunoassay were
tested in the bioassay along with their corresponding
pre-dose samples, even if the pre-dose samples did not
test positive in the immunoassay. If a sample was positive
in both the Biacore assay and the cell-based assay, the sub-
ject was defined as positive for neutralizing antibodies.
Exploratory B cell analysis
In the phase 1a study, whole blood specimens were col-
lected at screening visit day 1, pre-dose on the day ofdosing, post-dose on days 14 and 28 for all dose groups,
day 42 for the 3.0 and 6.0 mg/kg dose groups, and at the
extension/follow-up for all dose groups. In the phase 1b
study, whole blood specimens were collected twice be-
fore study inclusion (at screening day 28, re-screen);
pre-dose on day 1; post-dose on days 15, 29, 50, 64, 78,
110, 134, 164, 190, 218; and early termination (when ap-
plicable). Whole blood specimens were shipped at ambi-
ent temperature to ICON Central Laboratories within
the previously established 48-hour stability time frame
for standard hematology assessment and flow cytometry
determinations [data on file]. A standard clinical
hematology analyzer was used to enumerate total
lymphocyte counts. Detailed methods are provided else-
where [27].
Antibody combinations were chosen to permit enu-
meration of total B cells (CD19+CD20+), naïve B cells
(CD19+sIgD+CD27-), IgD+ memory B cells (CD19+sIgD
+CD27+), IgD- memory B cells (CD19+sIgD-CD27+),
total T cells (CD3+CD16/CD56-), and natural killer
cells (CD3-CD16/CD56+). Plasmablasts were previ-
ously assessed and determined not to be sufficiently stable
for assessment in the phase 1 studies [27]; although they
were analyzed in the phase 1a study, the data were not
used because of cell instability. The antibody configura-
tions and clone numbers were as follows: Tube 1: CD20
FITC (L27), CD45 APC (2D1), CD19 PerCP (SJ25C1);
Tube 2: CD3 FITC (SK7), CD16 PE (B73.1), CD56 PE
(MY31), CD45 APC (2D1); Tube 3: CD27 FITC (L128),
CD38 PE (HB7), CD19 PerCP (SJ25C1), CD45 APC (2D1);
Tube 4: CD27 FITC (L128), IgD PE (IA6-2), CD19 PerCP
(SJ25C1), CD45 APC (2D1), Tube 5: CD138 FITC (MI15),
CD38 PE (HB7), CD19 PerCP (SJ25C1), CD45 APC (2D1).
The entire panel was performed in the phase 1a study; in
the phase 1b study, the routine panel (tubes 1–3) was per-
formed at screening visit day 28, re-screen, and days 64,
110, 134, 164, and 190. The extended panel (all tubes) was
performed on phase 1b specimens drawn on days 1, 15, 29,
50, 78, 218, and early termination. Monitoring was not re-
quired if the change in B cell level was ≤ 20 %, or levels
had returned to either within 20 % of baseline or a level
from a reference range of healthy volunteers, whichever
was lower; subjects could be released from monitoring as
early as day 190. Those that did not meet these criteria
were asked to return monthly until the criteria were met
or they were released by medical board review.
Statistical analyses
Demographic, safety, pharmacokinetic, and B cell data
for each route and dose were analyzed with descriptive
statistics. After review, data were combined for the pla-
cebo groups by any route. The primary safety analysis
was performed for all subjects who received an investi-
gational product (blisibimod or placebo).
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in lymphocyte phenotypes was explored graphically
using a cubic spline [28] to visualize potential trends
over time by dose and route. After reviewing these
graphs, exploratory modeling of the relationship be-
tween dose/route and select lymphocyte phenotypes was
analyzed using a mixed-effects model, with baseline
value and actual treatment as fixed effects, and subject
as a random effect. Based on graphical review, post-dose
times were grouped as dosing (days 15–42), post-dosing
(days 43–100), and extended follow-up (> day 100)
phases, with exploratory modeling performed separately
for these three post-dose time ranges. Because they were
similar, blisibimod 1.0 mg/kg and 3.0 mg/kg dose groups
were pooled and compared with the placebo group for
each post-dose phase using an F test (P values reported
for these comparisons should be considered descriptive).
Reference ranges of the mean, standard error, and
coefficient of reliability of healthy volunteer and SLE
subsets were established in a previously published
study [27].
Results
Subject disposition and baseline characteristics
In the phase 1a study, 56 subjects were enrolled and
randomized; 54 were dosed. Two subjects (blisibimod,
n = 1; placebo, n = 1) did not receive the study drug
due to study ineligibility: the subject in the blisibimod
group developed an infection before dosing, and the
subject in the placebo group had a glomerular filtra-
tion rate < 60 mL/min. Only one subject (placebo)
was withdrawn from the phase 1a study due to a ser-
ious adverse event (SAE; see Safety and tolerability). In
the phase 1b study, 64 subjects were enrolled and ran-
domized; 63 were dosed. One blisibimod-assigned sub-
ject did not receive the study drug due to study
ineligibility (papillary lesion requiring an excision), and
one placebo-assigned subject who received blisibimod
instead of placebo at the fourth dose was excluded
from the analyses. Four subjects (blisibimod, n = 2;
placebo, n = 2) withdrew from the study due to an
AE: in the blisibimod cohort, AEs were migraine and
hypersensitivity, and in the placebo cohort, AEs were
cellulitis and abscessed limb. One additional subject
from the placebo group withdrew from the study at
the subject’s request.
Demographics and baseline disease characteristics
were similar between the treatment groups, with the ex-
ception of CD19 antigen median fluorescence intensity
(MFI), which was statistically significantly higher in the
blisibimod versus placebo group (Tables 1, 2). Concomi-
tant medication use was high, with a large portion of
subjects taking prednisone (39–45 %) and hydroxychlor-
oquine (38–63 %).Blisibimod pharmacokinetics
After single and four weekly IV injections, blisibimod
serum concentration-time profiles were biphasic: there
was an initial distribution phase followed by a slower
elimination phase (Fig. 1a, c). Based on C0 and AUC, ex-
posure increased in an approximate dose-proportional
manner from 1.0 to 6.0 mg/kg IV (Tables 3, 4). In the
single-dose cohorts, the mean t½,z for the 6.0 mg/kg IV
dose group was 8.7 days (Table 3); in the multiple-dose
cohort for the 6.0 mg/kg IV dose group, 12 days
(Table 4). The mean CL ranged from 47.5 to 51.9 mL/hr
after a single IV dose (Table 3) and 34 mL/hour after
multiple IV doses (Table 4). These similar CL values in-
dicate linear pharmacokinetics across a sixfold range of
1.0 to 6.0 mg/kg. Blisibimod exhibited a 2.3-fold AR
after the fourth dose compared with the first dose
(Table 4).
After single and four weekly SC injections, the median
tmax ranged from 47 to 49 hours post-dose, indicating
slow absorption with SC dosing (Tables 3, 4; Fig. 1b, c).
Based on AUC and Cmax, exposure to blisibimod in-
creased in an approximate dose-proportional manner
from 0.3 to 3.0 mg/kg SC (Table 3). After a single dose,
the mean t½,z over this tenfold dose range was 8.5 days
(Table 3); after the fourth weekly dose, 9.3 days (Table 4).
The mean apparent CL/F was 85.1 mL/hr after a single
dose and 72.9 mL/hr after multiple doses. Following four
weekly doses of blisibimod, moderate accumulation was
seen, with ratios ranging from 2.2 to 2.8 (Table 4).
Anti-blisibimod antibodies
In the phase 1a study, 19 of the 40 (48 %) blisibimod-
and four of the 13 (31 %) placebo-treated subjects were
positive for anti-blisibimod binding antibodies at any
time; none of these antibodies were neutralizing. In the
phase 1b study, 19 of the 49 (39 %) blisibimod- and
seven of the 14 (50 %) placebo-treated subjects were
positive for anti-blisibimod binding antibodies at any
time point; three (6 %) blisibimod-treated subjects were
positive for neutralizing antibodies in this study. All sub-
jects were negative for neutralizing antibodies at follow-
up visits at the end of the study.
Changes in lymphocyte populations following treatment
with blisibimod
Baseline flow cytometry variables measured in this study
were generally similar between the blisibimod and pla-
cebo groups (Table 5; Fig. 2a–d). Total lymphocytes, T
cells, and natural killer cells did not exhibit significant
changes relative to baseline. Three changes were ob-
served with blisibimod: first, a reduction of total B cells
(Fig. 2a, ≥ day 75; Table 5, day > 100, P = 0.006). Second,
disproportionate changes occurred within the subsets of
B cells that remained in the blood post-treatment: there
Table 1 Demographics and disease characteristics of patients with systemic lupus erythematosus in the phase 1a study
Blisibimod
Placebo mg/kg SC mg/kg IV All
Baseline characteristics (n = 14) 0.1 (n = 6) 0.3 (n = 6) 1.0 (n = 9) 3.0 (n = 6) 1.0 (n = 6) 3.0 (n = 1) 6.0 (n = 6) (N = 40)
Sex, n (%)
Female 13 (93) 5 (83) 6 (100) 8 (89) 6 (100) 6 (100) 1 (100) 6 (100) 38 (95)
Male 1 (7) 1 (17) 0 (0.0) 1 (11) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (5)
Race, n (%)
White 2 (14) 2 (33) 1 (17) 1 (11) 0 (0) 2 (33) 1 (100) 3 (50) 10 (25)
Black 5 (36) 5 (50) 3 (50) 1 (11) 2 (33) 1 (17) 0 (0) 2 (33) 12 (30)
Hispanic 7 (50) 0 (0) 2 (33) 7 (78) 4 (67) 3 (50) 0 (0) 0 (0) 16 (40)
Asian 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (17) 1 (3)
Pacific Islander 0 (0) 1 (17) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3)
Age (years)
Median 39.5 48.5 47.5 46.0 45.0 38.0 52.0 53.0 46.0
Range 21–55 32–53 30–52 31–55 36–53 28–55 – 32–55 28–55
Medications, n (%)
Prednisone (+ MePred) 7 (50) 3 (50) 1 (17) 7 (78) 4 (67) 3 (50) 1 (17) 0 (0) 18 (45)
Hydroxychloroquine 6 (43) 2 (33) 2 (33) 6 (67) 4 (67) 1 (17) 0 (0) 0 (0) 15 (38)
Azathioprine 4 (29) 3 (50) 1 (17) 3 (33) 1 (17) 1 (17) 0 (0) 0 (0) 9 (23)
Mycophenolate 4 (29) 0 (0) 2 (33) 3 (33) 1 (17) 0 (0) 1 (17) 0 (0) 7 (18)
Methotrexate 1 (7) 0 (0) 0 (0) 1 (11) 0 (0) 2 (33) 0 (0) 0 (0) 3 (8)
Anti-dsDNA, n 12 6 6 9 6 4 5 0 36
Median (range), IU/mLa 30 (30–300) 179 (30–300) 30 (30–206) 30 (30–300) 30 (30–187) 30 (30–294) 30 (30–40) – 30 (30–300)
C3 (IU,mL), median (range) 114 (58–168) 131 (76–189) 132 (104–188) 126 (95–187) 123 (63–154) 148 (95–173) 113 (111–120) – 125 (63–189)
C4 (IU,mL), median (range) 13 (5–38) 17 (13–40) 34 (12–38) 22 (13–44) 14 (9–30) 33 (23–40) 23 (18–31) – 23 (9–44)
Abbreviations: C3 complement 3, C4, complement 4, dsDNA double-stranded DNA, IV intravenous, MePred methylprednisolone, SC subcutaneous
aReference ranges are < 30 IU/mL for negative, 30–75 IU/mL for borderline, and > 75 UI/mL for positive for all age ranges
Stohl et al. Arthritis Research & Therapy  (2015) 17:215 Page 5 of 14was a decrease in the proportion of IgD+CD27- naïve B
cells (Fig. 2b, ≥ day 45; Table 5, day 43–100, P < 0.01)
and an increase in the proportion of IgD-CD27+ memory
B cells (Fig. 2d, > day 15; Table 5, day 15–42, P = 0.02).
Third, there was an increase in the fluorescent inten-
sity (i.e., antigen density) of CD19 (CD19 MFI,
Table 5, > day 100, P < 0.01) and a decrease in the
CD38 antigen on B cells (CD38 on B cells MFI, Table 5,
day 15–42, P < 0.01).
Safety and tolerability
In the phase 1a study, 28 (70 %) blisibimod- and 11
(79 %) placebo-treated subjects reported ≥ 1 AE
(Table 6). Two SAEs were reported: one each (8 %
each) in the blisibimod 3.0 mg/kg SC (17 %; ureteral
stones, hydronephrosis, and pyelonephritis; this sub-
ject continued in the study) and in the placebo co-
horts (7 %; pneumococcal pneumonia and bacteremia;
this subject withdrew from the study). Both SAEs were
considered by the investigator to be related to the study
medication.In the phase 1b study, 47 (96 %) blisibimod- and 12
(92 %) placebo-treated subjects reported ≥ 1 AE
(Table 7). Nine SAEs were reported in eight (13 %) sub-
jects (blisibimod, n = 5 across all dose groups [10 %];
placebo, n = 3 [23 %]). In the in the 0.3 mg/kg blisibi-
mod SC cohort, two subjects experienced SAEs: one a
polyarthritis lupus flare and the other severe depression
(8 % each). In the blisibimod 1.0 mg/kg SC cohort, one
subject experienced chest pain, pyrexia, and a moderate
increase in prothrombin time; in the 3.0 mg/kg SC co-
hort, one subject experienced moderate syncope (8 %
each). None of these SAEs were considered related to
the study drug and all subjects remained in the study. In
the blisibimod 6.0 mg/kg IV cohort, one (8 %) subject
experienced SAEs of severe sick sinus syndrome and
ECG QTc interval prolongation, which were considered
by the investigator to possibly be related to the study
drug; however, this subject remained in the study. In
the placebo cohort, SAEs of pericarditis and pericar-
dial effusion, mild SLE flare, and cellulitis were re-
ported in three subjects (23 %); none were considered
Table 2 Demographics and disease characteristics of patients with systemic lupus erythematosus in the phase 1b study
Blisibimod
Placebo mg/kg SC 6.0 mg/kg IV All
Baseline characteristics (n = 13) 0.3 (n = 12) 1.0 (n = 13) 3.0 (n = 12) (n = 12) (N = 49)
Sex, n (%)
Female 12 (92) 12 (100) 12 (92) 12 (100) 9 (75) 45 (92)
Male 1 (8) 0 (0) 1 (8) 0 (0) 3 (25) 4 (8)
Race, n (%)
White 6 (46) 7 (58) 9 (69) 4 (33) 5 (42) 25 (51)
Black 2 (15) 3 (25) 3 (23) 1 (8) 2 (17) 9 (18)
Hispanic 5 (38) 1 (8) 1 (8) 6 (50) 5 (42) 13 (27)
Asian 0 (0) 1 (8) 0 (0) 1 (8) 0 (0) 2 (4)
Pacific Islander
Age (years), median (range) 45.0 (22–64) 41.5 (21–62) 47.0 (34–63) 44.0 (24–66) 44.5 (26–62) 43.0 (21–66)
SLEDAI, median (range) 3 (0–11) 4 (0–6) 2 (0–14) 4 (0–12) 2 (0–10) 2 (0–14)
Medications, n (%)
Prednisone (+ MePred) 7 (54) 4 (33) 5 (38) 6 (50) 4 (33) 19 (39)
Hydroxychloroquine 13 (100) 4 (33) 9 (69) 9 (75) 9 (75) 31 (63)
Azathioprine 4 (31) 1 (8) 4 (31) 1 (8) 1 (8) 7 (14)
Mycophenolate 2 (15) 2 (17) 1 (8) 1 (8) 0 (0) 4 (8)
Methotrexate 0 (0) 1 (8) 0 (0) 1 (8) 1 (8) 3 (6)
Anti-dsDNA, n 13 12 13 11 12 48
Median (range), IU/mLa 36 (30–300) 30 (30–300) 36 (11–300) 30 (30–300) 30 (30–300) 30 (11–300)
C3 (IU/mL), median (range) 96 (47–167) 131 (78–179) 100 (65–266) 107 (74–160) 119 (82–168) 119 (65–266)
C4 (UI/mL), median (range) 20 (9–43) 19 (5–58) 23 (7–55) 21 (8–46) 23 (5–50) 21 (5–58)
Abbreviations: C3 complement 3, C4 compliment 4, dsDNA double-stranded DNA, IV intravenous, MePred methylprednisolone, SC subcutaneous, SLEDAI Systemic
Lupus Erythematosus Disease Activity Index
aReference ranges are < 30 IU/mL for negative, 30–75 IU/mL for borderline, and > 75 UI/mL for positive for all age ranges
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study.
One (8 %) subject in the phase 1b blisibimod 3.0 mg/kg
SC group had a significant change from baseline in
Fridericia QTc interval; no other clinically meaningful
changes in ECGs were seen. No clinically significant
drug-related trends were observed in clinical labora-
tory data or vital signs.
Discussion
In the present studies, treatment with blisibimod pro-
duced significant changes in B cell subpopulations and B
cell surface molecule density were observed, with no
notable changes in T cells or natural killer cells. There
was an initial transient increase of the B cell pool in sub-
jects treated with single or multiple doses of blisibimod,
but this was not statistically significant and was similar
to previous findings in SLE patients treated with the
BAFF antagonists atacicept [29, 30] and belimumab
[31, 32]. Blisibimod showed consistency in half-life
and linearity across dose ranges for both IV and SCroutes of administration, with half-life ranging from
7 to 12 days for the 0.3 to 6.0 mg/kg IV and SC dose
groups, and clearance estimates constant over the 1.0 to
6.0 mg/kg IV and SC doses ranging from 34 to 79 mL/hr.
The safety and tolerability of single or multiple SC or IV
doses of blisibimod were comparable with those associated
with placebo administration, and AE and treatment-
related events did not increase with increasing doses
of blisibimod.
The main finding of these studies was the statistically
significant decrease in B cell counts (Table 5, > day 100,
P = 0.10), although the reduction was not as large as
those seen during treatment with the lytic agent rituxi-
mab [33]. The constituency of the B cell pool also chan-
ged following treatment with blisibimod: there was a
decrease in the number of naïve B cells (24–76 % re-
duction, day 43–100) and a relative increase in the
memory B cell compartment, with the greatest effect
on IgD-CD27+ (53–154 % increase, day 15–42). One
possible mechanism for these results may be related
to differences in the expression profiles of BAFF
Fig. 1 Mean (SD) concentration-time profiles following administration of blisibimod in subjects with systemic lupus erythematosus. Subjects were
treated with the indicated single doses of blisibimod IV (a), SC (b), or the indicated weekly doses (c) for 4 weeks. Abbreviations: IV intravenous,
LOQ lower limit of quantification, SC subcutaneous, SD standard deviation
Table 3 Pharmacokinetic parameters and incidence of anti-blisibimod antibodies in patients with systemic lupus erythematosus in
the phase 1a study
mg/kg SC mg/kg IV
0.1 (n = 6) 0.3 (n = 6) 1.0 (n = 9) 3.0 (n = 6) 1.0 (n = 6) 3.0 (n = 1) 6.0 (n = 6)
Parameter, mean (SD)
tmax (hr) 48 (2.2–72) 48 (47–70) 48 (24–72) 47 (23–73) 0.61 ( 0.083–1.1) 0.083 0.42 (0.17–0.67)
Cmax or C0 (μg/hr) 0.273 (0.0817) 0.916 (0.397) 4.14 (1.54) 9.32 (2.57) 21.2 (4.11) 80.9 190
AUC0-t (hr*μg/mL) 50.0 (15.9) 252 (123) 1140 (384) 2770 (459) 1460 (543) 6610 9440 (1980)
t1/2,z (day) 4.0 (1.1) 6.5 (2.9) 9.8 (2.5) 8.4 (2.1) 7.9 (2.8) 8.4 8.7 (2.0)
CL/F or CL (mL/hr) 179 (62.2) 112 (49.4) 72.0 (26.9) 77.8 (24.7) 51.9 (6.96) 48.6 47.5 (7.54)
Antibodies, n (%)
Pre-dose only 0 (0) 3 (50) 0 (0) 0 (0) 1 (17) 0 (0) 0 (0)
Post-dose only 4 (67) 1 (17) 3 (33) 1 (17) 0 (0) 1 (17) 0 (0)
Pre- and post-dose 0 (0) 0 (0) 0 (0) 2 (33) 0 (0) 2 (33) 1 (100)
Abbreviations: AUC0-t plasma-concentration curve from time of treatment to the last measurable concentration, Cmax maximum observed serum concentration,
C0 estimated initial concentration after IV bolus dosing, CL clearance (CL), CL/F apparent clearance, IV intravenous, SC subcutaneous, SD standard deviation,
t1/2,z half-life, tmax time to Cmax
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Table 4 Pharmacokinetic parameters and incidence of anti-blisibimod antibodies in patients with systemic lupus erythematosus in
the phase 1b study
0.3 mg/kg SC (n = 12) 1.0 mg/kg SC (n = 13) 3.0 mg/kg SC (n = 12) 6.0 mg/kg IV (n = 12)
Parameter, mean (SD) Day 1 Day 22 Day 1 Day 22 Day 1 Day 22 Day 1 Day 22
tmax (hr) 47 (24–97) 48 (24–96) 49 (25–170) 26 (8–73) 47 (20–170) 49 (0.58–170) N/A N/A
Cmax or C0 (μg/hr) 1.18 (0.498) 2.13 (0.466) 3.84 (1.02) 8.21 (1.88) 13.2 (4.49) 34.6 (8.84) 243 (128) 315 (163)
AUC0-t (hr*μg/mL) 149 (54.7) 657 (203) 484 (100) 2780 (862) 1670 (479) 9450 (2850) 8100 (3740) 35600 (15600)
t1/2,z (day) NC 7.9 (1.3) NC 9.8 (1.6) NC 10 (2.4) NC 12 (2.4)
CL/F or CL (mL/hr) NC 79.7 (38.2) NC 78.2 (30.4) NC 59.9 (16.3) NC 34.0 (18.6)
AR 2.21 (0.74) 2.21 (0.52) 2.76 (0.89) 2.31 (0.34)
Antibodies, n (%)
Pre-dose only 0 (0) 1 (8) 1 (8) 1 (8)
Post-dose only 7 (58) 1 (8) 1 (8) 6 (50)
Pre- and post-dose 0 (0) 1 (8) 1 (8) 0 (0)
Neutralizing 2 (17) 1 (8) 0 (0) 0 (0)
Abbreviations: AR accumulation ratio, AUC0-t plasma-concentration curve from time of treatment to the last measurable concentration, Cmax maximum observed
serum concentration, C0 estimated initial concentration after IV bolus dosing, CL clearance (CL), CL/F apparent clearance, IV intravenous, NA not applicable, NC not
calculated, SC subcutaneous, SD standard deviation, t1/2,z half-life, tmax time to Cmax
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differentially support the stages of B cell development
[1–5]. The relative increase in the memory B cell com-
partment was not associated with safety signals or eleva-
tions of immunoglobulin or anti-blisibimod antibody
levels. In fact, when comparing these data with those of
healthy volunteers from our previous study [27], blisibi-
mod seemed to correct the B cell compartment to be
more like that of healthy subjects, suggesting that if
normalization of these cell types can be associated with
clinical improvement, these may be a treatment goal in
future studies.
Markers of the metabolic activity of targeted cells were
also examined, as BAFF deprivation might suppress ex-
cess metabolic activity of those cells that were not
depleted. The fluorescence intensity of CD19 was mea-
sured because CD19 is part of the signaling complex
that modulates the threshold of activation of the B cell
receptor, and it is known to exhibit genetic variations
that correlate to expression levels and autoimmunity
[34]. The changes in CD19 density were variable, with
increases of 119–154 % for all doses except 6.0 mg/kg
IV, which produced a 43 % reduction > day 100 (Table 5,
CD19 MFI day 43–100 and day > 100, P = 0.04 and
P < 0.01, respectively). However, interpretation of
these results is difficult because the CD19 MFI values at
baseline were statistically significantly different between
the blisibimod- and placebo-treated groups (Table 5;
CD19 on B cells MFI, pre-dose, P < 0.01). The variability
in this dataset may be due to inconsistencies in the la-
boratory methods that were used; however, as the coeffi-
cient of reliability from our validation exercises all
exceeded 0.8, it is more likely attributable to biologicvariability in our subject pool. Nonetheless, CD19 MFI
was increased during administration of blisibimod, rais-
ing the possibility that blisibimod promoted a reduction
in B cell activation that reversed the down-modulation of
CD19 from the B cell surface in SLE patients [35]. Reduc-
tion of CD38 was also seen in blisibimod-treated sub-
jects, occurring as early as day 15–42 of treatment
(Table 5; CD38 on B cells MFI, day 15–42, P < 0.01). This
brought the density of this marker to within the range
of healthy volunteers (362–384 vs. 295 CD38 on B
cells MFI).
Other agents that reduce the number of circulating B
cells have been tested in SLE: the anti-CD20 monoclonal
antibody rituximab, a targeted B cell depletor, has been
used in the clinical setting in patients with SLE despite
not being approved for use in this population [36, 37].
The anti-BAFF monoclonal antibody belimumab in two
phase 3 trials in SLE demonstrated improvements in
clinical measurements and biomarkers of disease activity
[22, 23], and is approved for the treatment of SLE in the
United States. The BAFF- and a proliferation-inducing
ligand (APRIL)-neutralizing atacicept also reduces B cell
counts in patients with SLE, underscoring the versatility of
options in modulating this pathway [29, 38]. The success
of belimumab and the absence of efficacy above standard
of care from the rituximab clinical trials may be multifac-
torial and may dependent on trial design, but these results
could suggest that efficacy in treating SLE may not solely
be a function of reductions in B cell numbers. Yet, the
positive results seen with belimumab confirm the possibil-
ity of therapeutic potential of BAFF antagonists in SLE.
A key question is whether agents that antagonize both
cell-bound and circulating BAFF (e.g., blisibimod or
Table 5 Lymphocyte counts and cell surface marker mean fluorescence intensity in phase 1b subjects with systemic lupus
erythematosus (SLE) treated with blisibimod or placebo compared with previously established reference ranges in healthy
subjects (HS)b [27]
Reference rangea Blisbimod (mg/kg)a
Assay HS SLEb CoRc Placebo 0.3 SC 1.0 SC 3.0 SC 6.0 IV P valued
Lymphocytes (mm3) 1915 (84) 1553 (129)e ND
Pre-dosef 1331 (700) 1653 (965) 1244 (458) 1677 (620) 1513 (707) 0.47
Day 15–42 1420 (61) 1632 (60) 1439 (59) 1408 (62) 1580 (59) 0.97
Day 43–100 1396 (74) 1390 (78) 1373 (72) 1357 (78) 1458 (74) 0.73
> Day 100 1432 (70) 1422 (71) 1286 (68) 1298 (73) 1305 (70) 0.10
T cells (mm3) 1544 (74) 1278 (109) 0.83
Pre-dosef 1112 (628) 1275 (757) 965 (320) 1356 (547) 1141 (547) 0.51
Day 15–42 1086 (67) 1242 (67) 1150 (65) 1130 (72) 1247 (65) 0.52
Day 43–100 1086 (69) 1151 (73) 1121 (67) 1061 (73) 1232 (69) 0.95
> Day 100 1151 (55) 1205 (55) 1068 (53) 1094 (57) 1139 (55) 0.29
NK cells (mm3) 161 (18) 119 (14) 0.80
Pre-dosee 75 (67) 87 (61) 120 (112) 103 (59) 124 (71) 0.46
Day 15–42 98 (12) 105 (12) 88 (12) 100 (13) 142 (12) 0.78
Day 43–100 116 (12) 112 (13) 99 (12) 119 (13) 112 (12) 0.67
> Day 100 108 (12) 106 (12) 102 (11) 112 (12) 115 (12) 0.92
CD19+CD20+ (mm3) 178 (17) 136 (15) 0.87
Pre-dosef 112 (68) 194 (147) 140 (160) 169 (172) 165 (155) 0.70
Day 15–42 140 (21) 213 (21) 150 (20) 146 (22) 194 (20) 0.76
Day 43–100 126 (17) 132 (18) 98 (17) 96 (18) 115 (17) 0.17
> Day 100 111 (15) 117 (15) 70 (14) 60 (15) 66 (15) 0.01
IgD+CD27+ (naïve, mm3) 123 (15) 101 (14) 0.88
Pre-dosef 73 (47) 138 (141) 110 (150) 131 (154) 91 (88) 0.70
Day 15–42 97 (14) 134 (15) 91 (14) 84 (15) 154 (14) 0.60
Day 43–100 89 (13) 82 (14) 53 (13) 32 (14) 69 (13) < 0.01
> Day 100 75 (12) 82 (13) 49 (11) 41 (13) 31 (13) 0.06
IgD+CD27+ (memory, mm3) 18.9 (2.0) 12.0 (2.2)e 0.80
Pre-dosef 10 (13) 13 (11) 7 (7) 9 (9) 6 (5) 0.44
Day 15–42 9 (3) 23 (3) 14 (3) 14 (3) 23 (3) 0.09
Day 43–100 8 (3) 14 (4) 14 (3) 11 (4) 25 (3) 0.31
> Day 100 7 (2) 7 (2) 7 (2) 5 (2) 7 (2) 0.67
IgD-CD27+ (memory, mm3) 24.5 (2.5) 14.1 (2.2)g 0.92
Pre-dosef 17 (17) 20 (11) 15 (11) 11 (7) 14 (10) 0.40
Day 15–42 15 (4) 37 (4) 24 (3) 28 (4) 32 (4) 0.02
Day 43–100 14 (4) 23 (4) 19 (4) 21 (4) 34 (4) 0.22
> Day 100 11 (3) 16 (3) 10 (3) 10 (3) 12 (3) 0.73
CD19 (MFI) 63.0 (1.7) 44.6 (2.7)g ND
Pre-dosef 70 (37) 44 (11) 68 (22) 57 (9) 76 (17) < 0.01
Day 15–42 69 (5) 68 (5) 75 (4) 76 (5) 74 (5) 0.19
Day 43–100 65 (7) 73 (8) 83 (6) 81 (7) 80 (7) 0.04
> Day 100 66 (5) 68 (5) 81 (4) 82 (5) 43 (5) <0.01
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Table 5 Lymphocyte counts and cell surface marker mean fluorescence intensity in phase 1b subjects with systemic lupus
erythematosus (SLE) treated with blisibimod or placebo compared with previously established reference ranges in healthy
subjects (HS)b [27] (Continued)
CD38 (on B cells; MFI) 295 (18) 486 (52)g ND
Pre-dosef 578 (477) 413 (175) 424 (374) 498 (197) 537 (292) 0.68
Day 15–42 608 (67) 362 (67) 384 (64) 363 (71) 352 (65) < 0.01
Day 43–100 625 (96) 386 (101) 607 (92) 397 (100) 463 (96) 0.30
> Day 100 477 (104) 421 (104) 879 (99) 654 (106) 439 (104) 0.02
Abbreviations: CoR coefficient of reliability, IV intravenous, MFI median fluorescence intensity, ND not determined, NK natural killer, SC subcutaneous, SD standard
deviation, SE standard error, SLE systemic lupus erythematosus
aTable values are mean (SE) for reference ranges, mean (SD) for pre-dose values and least squares mean (SE) for post-dose study periods
bReference range P values compare values from patients with mild-to-moderate SLE with those of HS
cCoR was calculated by dividing the inter-subject variability by the total variability (inter-subject + intra-subject variability). This provides a reference to assess the
reliability of a measure in detecting changes within a subject over time. A higher CoR indicates a measure that will be more reliable in detecting treatment effects
over time since the within (intra-) subject variability is low in repeat measures testing
dBlisibimod 1.0 mg/kg and 3.0 mg/kg dose groups were pooled and compared to placebo using an F-test to generate descriptive P values
eP value from 0.01 to < 0.05
fPre-dose is defined as the mean value of day 1 and the immediately preceding screen
gP value < 0.01
Fig. 2 B cell subsets following administration of blisibimod to subjects with systemic lupus erythematosus treated with the four indicated weekly
doses in the phase 1b study. B cell subsets are peripheral blood CD19+ CD20+ total B cells (a), IgD+ CD27- naïve B cells (b), IgD+ CD27+ memory
B cells (c), and IgD- CD27+ memory B cells (d). Each symbol represents an individual patient at the indicated time point, and lines were generated
by smoothing with a spline function
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Table 6 Adverse events (AE) occurring in ≥ 5 % of patients with systemic lupus erythematosus treated with blisibimod in the
phase 1a study
Blisibimod
Placebo mg/kg SC mg/kg IV All
n (%) (n = 14) 0.1 (n = 6) 0.3 (n = 6) 1.0 (n = 9) 3.0 (n = 6) 1.0 (n = 6) 3.0 (n = 1) 6.0 (n = 6) (N = 40)
Patients reporting an AE 11 (79) 5 (83) 3 (50) 4 (44) 5 (83) 5 (83) 1 (100) 5 (83) 28 (70)
Nausea 4 (29) 2 (33) 0 (0) 2 (22) 2 (33) 0 (0) 0 (0) 0 (0) 6 (15)
Headache 3 (21) 1 (17) 0 (0) 1 (11) 1 (17) 0 (0) 0 (0) 1 (17) 4 (10)
Upper respiratory tract infection 3 (21) 0 (0) 0 (0) 1 (11) 0 (0) 1 (17) 1 (100) 1 (17) 4 (10)
Diarrhea 1 (17) 0 (0) 0 (0) 1 (11) 1 (17) 0 (0) 0 (0) 1 (17) 3 (8)
Bronchitis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100) 1 (17) 2 (5)
Dizziness 4 (29) 0 (0) 0 (0) 1 (11) 1 (17) 0 (0) 0 (0) 0 (0) 2 (5)
Injection site prutitus 1 (7) 2 (33) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (5)
Pain in extremity 1 (7) 0 (0) 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 1 (17) 2 (5)
Pharyngolaryngeal pain 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (33) 0 (0) 0 (0) 2 (5)
Shoulder pain 0 (0) 2 (33) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (5)
Vomiting 1 (7) 0 (0) 0 (0) 1 (11) 1 (17) 0 (0) 0 (0) 0 (0) 2 (5)
Abbreviations: IV intravenous, SC subcutaneous
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than those that bind only to soluble BAFF (e.g.,
belimumab) [39]. In a 24-week, phase 2b, placebo-
controlled study of blisibimod in 547 patients with SLE,
treatment with blisibimod decreased B cell counts, re-
duced disease activity, and prolonged time to first severe
disease flare [40]. The reductions in B cell counts in this
study were comparable with those reported with beli-




n (%) (n = 13) 0.3 (n = 12)
Patients reporting an AE 12 (92) 12 (100)
Nasopharyngitis 1 (8) 2 (17)
Headache 0 (0) 0 (0)
Injection site erythema 0 (0) 0 (0)
Nausea 1 (8) 1 (8)
Injection site prutitus 0 (0) 0 (0)
Upper respiratory tract infection 0 (0) 3 (25)
Urinary tract infection 2 (15) 0 (0)
Arthralgia 2 (15) 1 (8)
Back pain 0 (0) 1 (8)
Diarrhea 3 (23) 1 (8)
Gastroesophogeal reflux disease 0 (0) 1 (8)
Systemic lupus 2 (15) 2 (17)
Abbreviations: IV intravenous, SC subcutaneoussome B cell reductions in phase 3 trials of the soluble
and bound BAFF antagonist tabulumab [41].
Little is known about the nature and purpose of
membrane-bound BAFF. The phenotype of genetically
engineered mice that express membrane-bound BAFF
and almost no soluble BAFF is similar to that of BAFF-
deficient mice, with marked reductions in B cells, serum
immunoglobulin (Ig) levels, and antigen-specific Ig re-
sponses [42]. Based on this, patients with SLE in whomstemic lupus erythematosus treated with blisibimod in the
6.0 mg/kg IV All
1.0 (n = 13) 3.0 (n = 12) (n = 12) (N = 49)
13 (100) 11 (92) 11 (92) 47 (96)
5 (38) 2 (17) 2 (17) 11 (22)
2 (15) 2 (17) 2 (17) 11 (22)
2 (31) 3 (25) 0 (0) 7 (17)
1 (8) 3 (25) 2 (17) 7 (14)
3 (23) 3 (25) 0 (0) 6 (12)
2 (15) 0 (0) 1 (8) 6 (12)
2 (15) 3 (25) 1 (8) 6 (12)
1 (8) 2 (17) 1 (8) 5 (10)
1 (8) 2 (17) 1 (8) 5 (10)
1 (8) 3 (25) 0 (0) 5 (10)
2 (15) 2 (17) 0 (0) 5 (10)
1 (8) 1 (8) 1 (8) 5 (10)
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neutralized may have a clinical response no different
from that of patients in whom only soluble BAFF has
been neutralized (e.g., belimumab). However, since ex-
pression of membrane-bound BAFF in the genetically
engineered mice was low [42], there may not have
been sufficient membrane-expressed BAFF to clarify
its function.
In addition to effects on B cells, BAFF can co-
stimulate in vitro proliferation of and cytokine produc-
tion by T cells [43, 44], and in mice it can skew in vivo
inflammatory responses toward a T helper (Th) 1 cell
profile and away from a Th2 cell profile in a B cell-
independent manner [45]. Moreover, BAFF promotes
generation of Th17 cells at least in part through direct
effects on T cells [46]. Whether membrane-expressed
BAFF might contribute to these BAFF-driven effects on
T cells is unknown.
These were a priori first-in-human studies, and the
reason for the large portion of subjects testing positive
for neutralizing antibodies is unknown. Ten and 4 % of
subjects in the phase 1a and 1b studies, respectively,
tested positive for antibodies prior to dosing. As previ-
ous use of an investigational product was an exclusion
criteria (belimumab was an investigational product at
the time of the studies), prior exposure to belimumab
would not explain these findings. Of the three subjects
who had neutralizing antibodies during the studies, the
nature and frequency of adverse events did not differ
from the group as a whole, and all three subjects were
negative for neutralizing antibodies at the end of the
study. Given that a large portion of the subjects in these
studies were positive for antibodies at any time, we be-
lieve this may be a characteristic of this population or
perhaps a limitation of the assay, which may require fur-
ther development [40].
A limitation of these studies is that this population
had mild stable or inactive disease (mean SLE Disease
Activity Index score of approximately 3) and baseline
immune-phenotypic profiles that were more similar to
those of the healthy population than patients with SLE
[27]. This may have made it difficult to appreciate sig-
nificant immunologic changes seen in these studies.
Moreover, many patients were being treated with immu-
nosuppressives and steroids, which could have impacted
baseline B cell levels. There were also some baseline differ-
ences between the dosing groups in some B cell measure-
ments. Although this most likely reflects the heterogeneity
of the population, this may have muted or amplified treat-
ment responses in these small treatment groups.
Conclusions
Single and multiple doses of blisibimod produced ap-
proximate dose-proportional pharmacokinetics acrossthe dosing range of 1.0–6.0 mg/kg, and significant
changes in B cell subpopulations and B cell surface mol-
ecule density. Blisibimod was well tolerated, with a safety
and tolerability profile similar to that of placebo. These
findings support the potential of BAFF antagonists such
as blisibimod in the treatment of SLE and other B cell-
mediated diseases. Larger clinical trials of blisibimod in
SLE should be advanced to assess its efficacy in SLE and
other autoimmune diseases in which B cells play an
important role in pathogenesis.
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